Cytokinetics CEO Robert Blum says there are key ways aficamten can enhance Camzyos. Aficamten has a more limited half-life than Camzyos, he said. This implies the medication leaves the patient’s body quicker. Doctors can expand the measurements quickly and ease side effects sooner.
The Food and Medication Organization requires patients taking Camzyos to get echocardiograms while their measurement is being expanded, and afterward at regular intervals all through treatment. He estimated that only 3 to 5 percent of patients with symptomatic HCM use Camzyos as a result.
“These evaluations render it strategically muddled for doctors” to recommend Camzyos, he said in a December interview with IBD.